The mpox vaccine is highly effective and infections are declining, according to two reports released last week by the Centers for Disease Control and Prevention (CDC).
The key finding: Review of “32,819 probable or confirmed U.S. mpox cases” found just 0.8% of those receiving the complete two-dose course of Bavarian Nordic's JYNNEOS vaccine became infected. The few infected after receiving the vaccine had milder infections than unvaccinated people, CDC says.
Cases drop: A U.S. outbreak of clade II of the mpox virus peaked in 2022, at about 3,000 cases a week, and dropped to 59 a week by April 30, with most cases among the unvaccinated, CDC says. The more-dangerous clade I virus is not reported in the U.S.
Why it matters: Vaccination eradicated smallpox, which is closely related to mpox, and vaccination contained the 2022 mpox outbreak. Approved against both clades of the virus, mpox vaccination is recommended for at-risk groups.
In addition to vaccines, there’s also an FDA-approved treatment, TPOXX, an antiviral made by SIGA Technologies.
The big picture: An ongoing outbreak of the deadlier clade I of the virus in the Democratic Republic of the Congo has caused more than 6,500 cases and 345 deaths so far this year, and clade II remains a global concern, says the World Health Organization (WHO). A global strategy, released Friday by WHO, calls for surveillance, communication, community outreach—and vaccination.